Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acadia Now Has The Cash To Finish Phase III On Its Own

This article was originally published in The Pink Sheet Daily

Executive Summary

After announcing promising Phase III data in late November, Acadia Pharmaceuticals conducted a private placement of nearly 20 million shares that will net the company $86.4 million in funds to continue running its Phase III program for pimavanserin in Parkinson’s disease psychosis.

You may also be interested in...



Pipelines, Not the Bottom Line, Define 2012 For Investors

More than two dozen biotechs offer 2x returns in 2012, as investors pin their hopes on some hematology oncology and CNS plays. Investors think the party may continue into next year, but perhaps not so giddily.

For Acadia’s Pimavanserin, The Second Time Is The Charm

Acadia’s serotonin 5-HT2A receptor blocker demonstrated efficacy in a Phase III trial in patients with Parkinson’s disease psychosis, giving the drug a second chance to reach the market. Pimavanserin previously failed to demonstrate efficacy in an original Phase III trial.

Phase III Efficacy Still Unproven, Pimavanserin Bags Acadia Deal With Biovail

First of two Phase III studies in Parkinson’s disease psychosis is set to yield data in the third quarter.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel